参考文献/References:
[1] Mills KT,Stefanescu A,He J. The global epidemiology of hypertension[J]. Nat Rev Nephrol ,2020,16(4):223-237.
[2] Lauder L,Mahfoud F,Azizi M,et al. Hypertension management in patients with cardiovascular comorbidities[J]. Eur Heart J ,2023,44(23):2066-2077.
[3] Wang JG,Zhang W,Li Y,et al. Hypertension in China:epidemiology and treatment initiatives[J]. Nat Rev Cardiol ,2023,20(8):531-545.
[4] Krum H,Schlaich M,Whitbourn R,et al. Catheter-based renal sympathetic denervation for resistant hypertension:a multicentre safety and proof-of-principle cohort study[J]. Lancet , 2009,373(9671):1275-1281.
[5] Symplicity HTN-2 Investigators,Esler MD,Krum H,et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial):a randomised controlled trial[J]. Lancet ,2010,376(9756):1903-1909.
[6] Bhatt DL,Kandzari DE,O’Neill WW,et al. A controlled trial of renal denervation for resistant hypertension[J]. N Engl J Med ,2014,370(15):1393-1401.
[7] Townsend RR,Mahfoud F,Kandzari DE,et al. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED):a randomised,sham-controlled,proof-of-concept trial[J]. Lancet,2017,390(10108):2160-2170.
[8] Kandzari DE,B?hm M,Mahfoud F,et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs:6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial[J]. Lancet ,2018,391(10137):2346-2355.
[9] Mahfoud F,B?hm M,Schmieder R,et al. Effects of renal denervation on kidney function and long-term outcomes:3-year follow-up from the Global SYMPLICITY Registry[J]. Eur Heart J ,2019,40(42):3474-3482.
[10] Azizi M,Schmieder RE,Mahfoud F,et al. Six-month results of treatment-blinded medication titration for hypertension control after randomization to endovascular ultrasound renal denervation or a sham procedure in the RADIANCE-HTN SOLO trial[J]. Circulation ,2019,139(22):2542-2553.
[11] Azizi M,Sanghvi K,Saxena M,et al. Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO):a randomised,multicentre,single-blind,sham-controlled trial[J]. Lancet,2021,397(10293):2476-2486.
[12] Azizi M,Mahfoud F,Weber MA,et al. Effects of renal denervation vs sham in resistant hypertension after medication escalation:prespecified analysis at 6 months of the RADIANCE-HTN TRIO randomized clinical trial[J]. JAMA Cardiol ,2022,7(12):1244-1252.
[13] Azizi M,Saxena M,Wang Y,et al. Endovascular Ultrasound Renal Denervation to Treat Hypertension:the RADIANCE Ⅱ randomized clinical trial[J]. JAMA ,2023,329(8):651-661.
[14] 鄢学,吴兰兰,殷跃辉. 压力反射刺激疗法治疗顽固性高血压[J]. 心血管病学进展,2015,36(1):48-51.
[15] Scheffers IJ,Kroon AA,Schmidli J,et al. Novel baroreflex activation therapy in resistant hypertension:results of a European multi-center feasibility study[J]. J Am Coll Cardiol ,2010,56(15):1254-1258.
[16] Bisognano JD,Bakris G,Nadim MK,et al. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension:results from the double- blind,randomized,placebo-controlled Rheos Pivotal trial[J]. J Am Coll Cardiol ,2011,58(7):765-773.
[17] Bakris GL,Nadim MK,Haller H,et al. Baroreflex activation therapy provides durable benefit in patients with resistant hypertension:results of long-term follow-up in the Rheos Pivotal Trial[J]. J Am Soc Hypertens ,2012,6(2):152-158.
[18] de Leeuw PW,Bisognano JD,Bakris GL,et al. Sustained reduction of blood pressure with baroreceptor activation therapy:results of the 6-year open follow-up[J]. Hypertension ,2017,69(5):836-843.
[19] Wallbach M,Lehnig LY,Schroer C,et al. Effects of baroreflex activation therapy on ambulatory blood pressure in patients with resistant hypertension[J]. Hypertension ,2016,67(4):701-709.
[20] Halbach M,Hickethier T,Madershahian N,et al. Acute on/off effects and chronic blood pressure reduction after long-term baroreflex activation therapy in resistant hypertension[J]. J Hypertens ,2015,33(8):1697-1703.
[21] Wallbach M,Born E,K?mpfer D,et al. Long-term effects of baroreflex activation therapy:2-year follow-up data of the BAT Neo system[J]. Clin Res Cardiol ,2020,109(4):513-522.
[22] Spiering W,Williams B,Van der Heyden J,et al. Endovascular baroreflex amplification for resistant hypertension:a safety and proof-of-principle clinical study[J]. Lancet ,2017,390(10113):2655-2661.
[23] van Kleef M,Devireddy CM,van der Heyden J,et al. Treatment of resistant hypertension with endovascular baroreflex amplification:3-year results from the CALM-FIM study[J]. JACC Cardiovasc Interv ,2022,15(3):321-332.
[24] Lobo MD,Sobotka PA,Stanton A,et al. Central arteriovenous anastomosis for the treatment of patients with uncontrolled hypertension(the ROX CONTROL HTN study):a randomised controlled trial[J]. Lancet ,2015,385(9978):1634-1641.
[25] Lobo MD,Ott C,Sobotka PA,et al. Central iliac arteriovenous anastomosis for uncontrolled hypertension:one-year results from the ROX CONTROL HTN trial[J]. Hypertension ,2017,70(6):1099-1105.
[26] Jung S,Ott C,Karg MV,et al. Application of a central iliac arteriovenous coupler device in severe treatment-resistant hypertension:a 3.5-year follow-up[J]. J Hypertens ,2018,36(12):2471-2477.
[27] Neuzil P,Merkely B,Erglis A,et al. Pacemaker-mediated programmable hypertension control therapy[J]. J Am Heart Assoc ,2017,6(12):e006974.
[28] Kalarus Z,Merkely B,Neu?il P,et al. Pacemaker-based cardiac neuromodulation therapy in patients with hypertension:a pilot study[J]. J Am Heart Assoc ,2021,10(16):e020492.
[29] Green AL,Wang S,Bittar RG,et al. Deep brain stimulation:a new treatment for hypertension?[J]. J Clin Neurosci ,2007,14(6):592-595.
[30] Ems R,Garg A,Ostergard TA,et al. Potential deep brain stimulation targets for the management of refractory hypertension[J]. Front Neurosci ,2019,13:93.
[31] Groenland EH,Spiering W. Baroreflex amplification and carotid body modulation for the treatment of resistant hypertension[J]. Curr Hypertens Rep ,2020,22(4):27.
[32] Schlaich M,Schultz C,Shetty S,et al. 1416Transvenous carotid body ablation for resistant hypertension:main results of a multicentre safety and proof-of-principle cohort study[J]. Eur Heart J,2018,39(suppl_1):suppl_1.
[33] Brown JM,Siddiqui M,Calhoun DA,et al. The unrecognized prevalence of primary aldosteronism:a cross-sectional study[J]. Ann Intern Med ,2020,173(1):10-20.
[34] Mulatero P,Stowasser M,Loh KC,et al. Increased diagnosis of primary aldosteronism,including surgically correctable forms,in centers from five continents[J]. J Clin Endocrinol Metab ,2004,89(3):1045-1050.
[35] Reincke M,Bancos I,Mulatero P,et al. Diagnosis and treatment of primary aldosteronism[J]. Lancet Diabetes Endocrinol ,2021,9(12):876-892.
[36] Rossi GP,Rossitto G,Amar L,et al. Clinical outcomes of 1625 patients with primary aldosteronism subtyped with adrenal vein sampling[J]. Hypertension ,2019,74(4):800-808.
[37] Ota H,Seiji K,Kawabata M,et al. Dynamic multidetector CT and non-contrast-enhanced MR for right adrenal vein imaging:comparison with catheter venography in adrenal venous sampling[J]. Eur Radiol ,2016,26(3):622-630.
[38] Jiang X,Dong H,Peng M,et al. A novel method of adrenal venous sampling via an antecubital approach[J]. Cardiovasc Intervent Radiol ,2017,40(3):388-393.
[39] 阮浩航,董徽,安宣齐,等. 下导静脉显影是右侧肾上腺静脉插管成功的可靠标志[J]. 中国循环杂志,2023,38(8):839-844.
[40] Xiong H,Du L,Yang J,et al. The left adrenal vein:an important direction for right adrenal venous sampling[J]. J Clin Hypertens(Greenwich),2023,25(12):1145-1150.
[41] 董徽,蒋雄京,关婷,等. 经皮超选择性肾上腺动脉栓塞治疗原发性醛固酮增多症[J]. 中华高血压杂志,2013,21(6):536-541.
[42] Dong H,Zou Y,He J,et al. Superselective adrenal arterial embolization for idiopathic hyperaldosteronism:12-month results from a proof-of-principle trial[J]. Catheter Cardiovasc Interv ,2021,97 Suppl 2:976-981.
[43] Qiu J,Li N,Xiong HL,et al. Superselective adrenal arterial embolization for primary aldosteronism without lateralized aldosterone secretion:an efficacy and safety,proof-of-principle study[J]. Hypertens Res ,2023,46(5):1297-1310.
[44] Sun F,Liu X,Zhang H,et al. Catheter-based adrenal ablation:an alternative therapy for patients with aldosterone-producing adenoma[J]. Hypertens Res ,2023,46(1):91-99.
[45] Zhang H,Li Q,Liu X,et al. Adrenal artery ablation for primary aldosteronism without apparent aldosteronoma:an efficacy and safety,proof-of-principle trial[J]. J Clin Hypertens (Greenwich) ,2020,22(9):1618-1626.
相似文献/References:
[1]孙刚,黄冠华,综述.高血压合并心力衰竭的治疗策略[J].心血管病学进展,2016,(2):201.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.027]
SUN Gang,HUANG Guanhua.Treatment Strategy of Hypertension with Heart Failure[J].Advances in Cardiovascular Diseases,2016,(3):201.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.027]
[2]范贵娟,综述,徐瑞,等.盐敏感性高血压的研究进展[J].心血管病学进展,2016,(4):364.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.010]
FAN Guijuan,XU Rui.Research Progress of Salt Sensitive Hypertension[J].Advances in Cardiovascular Diseases,2016,(3):364.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.010]
[3]陈源源.钙通道阻滞剂在降压治疗中的应用[J].心血管病学进展,2015,(6):662.[doi:10.3969/j.issn.1004-3934.2015.06.002]
CHEN Yuanyuan.Application of Calcium Channel Blockers in Hypertension Treatment[J].Advances in Cardiovascular Diseases,2015,(3):662.[doi:10.3969/j.issn.1004-3934.2015.06.002]
[4]张瑞 毛露 孙硕 Dirk Hermann 陈艾东.内皮素-1干预成为高血压治疗新靶点的展望[J].心血管病学进展,2019,(7):969.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.000]
ZHANG Rui MAO LuSUN ShuoDIRK Hermann CHEN Aidong.The Prospect of Endothelin-1 Intervention as A New Target for the Treatment of Hypertension[J].Advances in Cardiovascular Diseases,2019,(3):969.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.000]
[5]张毅,柳志红.动态血压监测在高血压中的应用现状与问题[J].心血管病学进展,2019,(6):848.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.003]
ZHANG Yi,LIU Zhihong.Current status and nsolved Pproblems of Ambulatory Blood Pressure Monitoring for the Management of Hypertension[J].Advances in Cardiovascular Diseases,2019,(3):848.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.003]
[6]黄秋瑾 胡蓉.高血压合并糖尿病患者血压控制率和控制目标的探讨[J].心血管病学进展,2019,(7):973.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.002]
HUANG QiujinHU Rong.Discussion on Blood Pressure Control Rate and Control Target in Patients with Hypertension Complicated with Diabetes[J].Advances in Cardiovascular Diseases,2019,(3):973.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.002]
[7]张旭明 王曦.高血压对认知功能的影响[J].心血管病学进展,2019,(7):977.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.003]
ZHANG Xuming,WANG Xi.The Relationship Between Hypertension and Cognitive Function[J].Advances in Cardiovascular Diseases,2019,(3):977.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.003]
[8]凌梦军 陈明凌梦军.阻塞性睡眠呼吸暂停低通气综合征与高血压关系的研究进展[J].心血管病学进展,2019,(5):722.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.015]
[9]李波 郭毅 田进文 邓珏琳.高血压合并2型糖尿病的治疗进展[J].心血管病学进展,2019,(9):1196.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.002]
LI Bo,GUO Yi,TIAN Jinwen,et al.Therapy in Hypertensive Patients with Type 2 Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2019,(3):1196.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.002]
[10]王继航 赵施皓 李开亮 田进文 李玉龙 付士辉 沈明志 邓珏琳.远程医疗在高血压病管理中的研究进展[J].心血管病学进展,2019,(9):1199.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.003]
WANG Jihang,ZHAO Shihao,LI Kailiang,et al.Telemedicine in Hypertension Management[J].Advances in Cardiovascular Diseases,2019,(3):1199.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.003]